Financial Statements

Jounce Therapeutics, Inc. (JNCE)

$4.07

+0.09 (+2.26%)
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers are in thousands

Retained Earning Schedule

Year 2021 2020 2019 2018 2017
Retained Earnings (Previous Year) -151-107-164-90-
Net Income -0-4457-27-16
Stock Dividends -91--0-47-73
Dividend Paid -----
Retained Earnings -242-151-107-164-90

PPE Schedule

Year 2021 2020 2019 2018 2017
Gross PPE 22281416-
Annual Depreciation -5-616-131
Capital Expenditure -0-0-1-1-15
Net PPE 1722281416

Intangible and Goodwill Schedule

Year 2021 2020 2019 2018 2017
Intangible and Goodwill (Previous Year) -----
New Purchases -180-253-189-86-130
Intangible and Goodwill -----

Jounce Therapeutics, Inc. income statement is the only one that provides an overview of company sales and net income
The reasoning behind the adjustment, however, is that free cash flow is meant to measure money being spent right now, not transactions that happened in the past. This makes Jounce Therapeutics, Inc. FCF a useful instrument for identifying growing companies with high up-front costs, which may eat into earnings now but have the potential to pay off later.